Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis

Table 2 Protein levels of uPA system components in tumour tissue specimens in relation to clinicopathological parameters of the ccRCC patients

Clinicopathological parameters	No. patients	uPA^a	uPAR^a	PAI-1^a
Total	112	0.41 (0.4)	0.51 (0.7)	10.31 (20.7)
Gender ^b		P = 0.002	P = 0.065	P = 0.056
male	65	0.47 (0.6)	0.60 (0.7)	12.58 (29.1)
female	47	0.30 (0.3)	0.42 (0.5)	7.18 (13.9)
Age (years) ^b		P = 0.117	P = 0.029	P = 0.242
≤64	57	0.36 (0.3)	0.43 (0.4)	8.98 (13.4)
>64	55	0.46 (0.7)	0.63 (0.7)	11.74 (54.7)
Tumour stage ^b		P = 0.003	P = 0.021	P = 0.010
pT1+2	87	0.36 (0.3)	0.47 (0.5)	8.33 (14.0)
pT3+4	25	0.63 (0.9)	0.81 (1.4)	18.05 (62.3)
Tumour grade ^b		P = 0.122	P = 0.008	P = 0.011
G1+2	68	0.40 (0.3)	0.43 (0.5)	7.83 (12.8)
G3+4	44	0.43 (0.9)	0.68 (1.1)	14.57 (62.9)
Disease-specific survival ^b		P = 0.220	P = 0.002	P = 0.007
alive	91	0.37 (0.4)	0.46 (0.5)	7.91 (14.4)
died of ccRCC	21	0.50 (0.7)	0.94 (0.8)	16.08 (65.0)
Overall survival ^b		P = 0.568	P = 0.013	P = 0.037
alive	74	0.38 (0.4)	0.45 (0.4)	7.59 (17.7)
died of any cause	38	0.46 (0.5)	0.69 (0.7)	12.57 (57.1)

^aMedian values (interquartile range), ng analyte/mg protein; ^bMann-Whitney test.

ISSN: 1471-2407